How does benralizumab's mechanism differ from other IL-5 biotherapeutics for severe asthma?
['["Since IL-5 plays an important role in the maturation, survival and migration of eosinophils, hence the pathogenesis of eosinophilic asthma, biotherapeutics targeting IL-5/IL-5R\\u03b1 have been developed and/or marketed, including Mepolizumab, Reslizumab, and Benralizumab.", "Mepolizumab, reslizumab, and benralizumab target IL-5, a key cytokine for eosinophils.", "Benralizumab is a humanized, afucosylated, anti-interleukin-5 receptor \\u03b1, immunoglobulin G (IgG)1\\u03ba monoclonal antibody.", "A global meta-analysis was first conducted followed by an indirect comparison of each IL-5-targeting drug: benralizumab, reslizumab and mepolizumab. ", "These include monoclonal antibodies against IL-5 or IL-5 receptor alpha (mepolizumab, reslizumab, and benralizumab), IL-13 (lebrikizumab and tralokinumab), IL-4 receptor alpha (dupilumab), IgE (omalizumab), and anti-thymic stromal lymphopoietin (tezepelumab) and small molecule therapies such as prostaglandin D2blockers (fevipiprant and timapiprant).", "However, there is research underway investigating interleukin-based monoclonal antibodies such as benralizumab, an anti-IL-5R monoclonal antibody which is currently in phase III clinical development. ", "BACKGROUND: Benralizumab is a humanised, anti-interleukin 5 receptor \\u03b1 monoclonal antibody that directly and rapidly depletes eosinophils, reduces asthma exacerbations, and improves lung function for patients with severe eosinophilic asthma. ", ". We investigated whether benralizumab, a monoclonal antibody directed against the alpha subunit of the interleukin-5 receptor that significantly reduces the incidence of asthma exacerbations, was also effective as an oral glucocorticoid-sparing therapy in patients relying on oral glucocorticoids to manage severe asthma associated with eosinophilia.", "Benralizumab--a humanized mAb to IL-5R\\u03b1 with enhanced antibody-dependent cell-mediated cytotoxicity--a novel approach for the treatment of asthma.", "Benralizumab is a monoclonal antibody that binds the \\u03b1 subunit of the receptor to IL-5.", "We assessed the safety and efficacy of benralizumab, a monoclonal antibody against interleukin-5 receptor \\u03b1 that depletes eosinophils by antibody-dependent cell-mediated cytotoxicity, for patients with severe, uncontrolled asthma with eosinophilia.", "While previous monoclonal antibodies against the IL-5 ligand resulted in inconsistent improvements in asthma outcomes, benralizumab has shown promise.", "Benralizumab is a monoclonal antibody against IL-5 receptor, and has an enhanced antibody dependent cell-mediated cytotoxicity function.", "Anti-IL-5-based therapies (mepolizumab and reslizumab are humanized monoclonal antibodies (hmAbs) that recognize free IL-5, benralizumab is a hmAb directed at the \\u03b1 subunit of the IL-5R) target the IL-5-signaling in eosinophilic asthma.", "Benralizumab is a humanised, afucosylated, anti-interleukin-5 receptor \\u03b1 monoclonal antibody that induces direct, rapid, and nearly complete depletion of eosinophils.", "Benralizumab is a humanized anti-IL5 receptor \\u03b1 (IL5R\\u03b1) monoclonal antibody (mAb) with enhanced (afucosylation) antibody-dependent cell-mediated cytotoxicity (ADCC) function.", "BACKGROUND: Benralizumab is a humanised, afucosylated, anti-interleukin-5 receptor \\u03b1 monoclonal antibody that induces direct, rapid, and nearly complete depletion of eosinophils.", "Benralizumab is a monoclonal antibody that targets interleukin-5 receptor \\u03b1 to de', '["Since IL-5 plays an important role in the maturation, survival and migration of eosinophils, hence the pathogenesis of eosinophilic asthma, biotherapeutics targeting IL-5/IL-5R\\u03b1 have been developed and/or marketed, including Mepolizumab, Reslizumab, and Benralizumab.", "Mepolizumab, reslizumab, and benralizumab target IL-5, a key cytokine for eosinophils.", "Benralizumab is a humanized, afucosylated, anti-interleukin-5 receptor \\u03b1, immunoglobulin G (IgG)1\\u03ba monoclonal antibody.", "A global meta-analysis was first conducted followed by an indirect comparison of each IL-5-targeting drug: benralizumab, reslizumab and mepolizumab. ", "These include monoclonal antibodies against IL-5 or IL-5 receptor alpha (mepolizumab, reslizumab, and benralizumab), IL-13 (lebrikizumab and tralokinumab), IL-4 receptor alpha (dupilumab), IgE (omalizumab), and anti-thymic stromal lymphopoietin (tezepelumab) and small molecule therapies such as prostaglandin D2blockers (fevipiprant and timapiprant).", "However, there is research underway investigating interleukin-based monoclonal antibodies such as benralizumab, an anti-IL-5R monoclonal antibody which is currently in phase III clinical development. ", "BACKGROUND: Benralizumab is a humanised, anti-interleukin 5 receptor \\u03b1 monoclonal antibody that directly and rapidly depletes eosinophils, reduces asthma exacerbations, and improves lung function for patients with severe eosinophilic asthma. ", ". We investigated whether benralizumab, a monoclonal antibody directed against the alpha subunit of the interleukin-5 receptor that significantly reduces the incidence of asthma exacerbations, was also effective as an oral glucocorticoid-sparing therapy in patients relying on oral glucocorticoids to manage severe asthma associated with eosinophilia.", "Benralizumab--a humanized mAb to IL-5R\\u03b1 with enhanced antibody-dependent cell-mediated cytotoxicity--a novel approach for the treatment of asthma.", "Benralizumab is a monoclonal antibody that binds the \\u03b1 subunit of the receptor to IL-5.", "We assessed the safety and efficacy of benralizumab, a monoclonal antibody against interleukin-5 receptor \\u03b1 that depletes eosinophils by antibody-dependent cell-mediated cytotoxicity, for patients with severe, uncontrolled asthma with eosinophilia.", "While previous monoclonal antibodies against the IL-5 ligand resulted in inconsistent improvements in asthma outcomes, benralizumab has shown promise.", "Benralizumab is a monoclonal antibody against IL-5 receptor, and has an enhanced antibody dependent cell-mediated cytotoxicity function.", "Anti-IL-5-based therapies (mepolizumab and reslizumab are humanized monoclonal antibodies (hmAbs) that recognize free IL-5, benralizumab is a hmAb directed at the \\u03b1 subunit of the IL-5R) target the IL-5-signaling in eosinophilic asthma.", "Benralizumab is a humanised, afucosylated, anti-interleukin-5 receptor \\u03b1 monoclonal antibody that induces direct, rapid, and nearly complete depletion of eosinophils.", "Benralizumab is a humanized anti-IL5 receptor \\u03b1 (IL5R\\u03b1) monoclonal antibody (mAb) with enhanced (afucosylation) antibody-dependent cell-mediated cytotoxicity (ADCC) function.", "BACKGROUND: Benralizumab is a humanised, afucosylated, anti-interleukin-5 receptor \\u03b1 monoclonal antibody that induces direct, rapid, and nearly complete depletion of eosinophils.", "Benralizumab is a monoclonal antibody that targets interleukin-5 receptor \\u03b1 to de']
Benralizumab's mechanism differs from other IL-5 biotherapeutics for severe asthma in that it directly and rapidly depletes eosinophils through antibody-dependent cell-mediated cytotoxicity, reduces asthma exacerbations, and improves lung function for patients with severe eosinophilic asthma.
[]